Brief: Epigenomics receives FDA approval for Epi proColon
13/04/2016 07:07
April 13 (Reuters) - Epigenomics AG ECXn.DE :
* U.S. Food and Drug Administration (FDA) has approved company's lead product, Epi proColon,
first and only FDA-approved blood-based colorectal cancer screening test
Source text for Eikon: ID:nEQ2Cyd67a
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns